Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| FE FENCFennec Pharmaceuticals | $11.29-0.5% | $395.9M | 1 assetsStage unavailable | No dated catalyst | |
| FG FGENFibroGen Inc | $9.71+7.6% | $39.3M | 13 assetsPhase 2 | FG-3246 (ADC)Phase 2 · Data readout | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $7.07+0.9% |
| $419.9M |
5 assetsStage unavailable |
| No dated catalyst |
| FI FIXXHomology Medicines | $13.52-2.2% | — | 3 assetsStage unavailable | No dated catalyst |
| FN FNCHFinch Therapeutics | $7.30+0.0% | $14.8M | 2 assetsStage unavailable | No dated catalyst |
| FO FOLDAmicus Therapeutics | $14.49+0.0% | $4.55B | 2 assetsStage unavailable | No dated catalyst |
| FR FRLNFreeline Therapeutics | $6.48+0.0% | $28.2M | 3 assetsStage unavailable | No dated catalyst |
| FU FULCFulcrum Therapeutics | $3.83-0.5% | $292.2M | 3 assetsStage unavailable | No dated catalyst |
| FU FUSNFusion Pharmaceuticals | $21.55+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| GA GALTGalectin Therapeutics | $3.68+3.1% | $371.1M | 3 assetsStage unavailable | No dated catalyst |
| GA GANXGain Therapeutics | $2.01+1.3% | $87.5M | 2 assetsStage unavailable | No dated catalyst |
| GE GENBGenerate Biomedicines | $16.12+0.8% | $2.07B | 4 assetsPhase 1b | GB-0895Phase 1b · Data readout |
| GE GERNGeron Corporation | $1.52-1.9% | $976.6M | 4 assetsStage unavailable | No dated catalyst |
| GH GHRSGH Research | $28.33-1.2% | $1.94B | 4 assetsPhase 2a | GH001 (inhalable mebufotenin) (5-MeO-DMT) Phase 2a · Data readout |
| GI GILDGilead Sciences | $146.12+1.9% | $181.18B | 23 assetsApproved | Bictegravir/Lenacapavir (BIC/LEN) (Antiretroviral Combination)PDUFA · Approval decision |
| GK GKOSGlaukos Corporation | $184.89+0.0% | $10.91B | 6 assetsStage unavailable | No dated catalyst |
| GL GLPGGalapagos NV | $27.73+0.0% | $1.86B | 14 assetsStage unavailable | No dated catalyst |
| GL GLSGelesis Holdings Inc | $0.16+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| GL GLSIGreenwich LifeSciences | $16.67+8.9% | $244.7M | 1 assetsPhase 3 | No dated catalyst |
| GL GLTOGalecto | $30.82+1.7% | $1.73B | 9 assetsStage unavailable | No dated catalyst |
| GL GLUEMonte Rosa Therapeutics | $14.30-3.2% | $1.22B | 4 assetsPhase 1 | MRT-8102Phase 1 · Data readout |
| GL GLYCGlycoMimetics Inc | $0.16+0.0% | $10.1M | 7 assetsStage unavailable | No dated catalyst |
| GM GMABGenmab | $33.45+0.1% | $20.56B | 14 assetsPhase 3 | Epkinly/Epcoritamab (GEN3013) (CD3-CD20 Bispecific) + R-CHOPPhase 2/3 · Data readout |
| GM GMDAGamida Cell | $0.03+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| GN GNLXGenelux Corporation | $2.72-0.7% | $123.1M | 4 assetsPhase 3 | Olvi-Vec (Olvimulogene nanivacirepvec)Phase 2 · Data readout |
| GN GNPXGenprex | $3.95+0.0% | $5.1M | 4 assetsPhase 1/2 | REQORSA (quaratusugene ozeplasmid) + TecentriqPhase 1/2 · Data readout |
| GN GNTAGenenta Science | $1.26+5.9% | $60.8M | 1 assetsStage unavailable | No dated catalyst |
| GO GOSSGossamer Bio | $0.15-1.8% | $75.6M | 5 assetsStage unavailable | No dated catalyst |
| GP GPCRStructure Therapeutics | $49.09-2.8% | $3.50B | 7 assetsPhase 2 | Aleniglipron (GSBR-1290)Phase 2 · Data readout |
| GR GRCEGrace Therapeutics | $2.20+2.8% | $46.3M | 3 assetsStage unavailable | No dated catalyst |
| GR GRCLGracell Biotechnologies | $10.25+0.0% | $989.9M | 3 assetsStage unavailable | No dated catalyst |
| GR GRIGRI Bio Inc. | $1.65-1.2% | $3.6M | 3 assetsStage unavailable | No dated catalyst |
| GR GRTSGritstone Oncology | $0.03+0.0% | $3.8M | 3 assetsStage unavailable | No dated catalyst |
| GR GRTXGalera Therapeutics | $16.28-2.5% | $3.38B | 9 assetsPhase 2 | Tilarginine + nab-paclitaxel + alpelisib Phase 1/2 · Data readout |
| GS GSKGSK | $52.41+0.9% | $104.97B | 28 assetsApproved | Zidesamtinib (NVL-520)PDUFA · Approval decision |
| GT GTHXG1 Therapeutics | $7.15+0.0% | — | 8 assetsStage unavailable | No dated catalyst |
| GU GUTSFractyl Health | $0.78+13.9% | $124.2M | 3 assetsPhase 2 | RevitaPhase 2 · Data readout |
| GY GYREGyre Therapeutics Inc | $6.91-1.6% | $732.7M | 14 assetsStage unavailable | No dated catalyst |
| HA HALOHalozyme Therapeutics | $108.17+1.9% | $12.28B | 14 assetsStage unavailable | No dated catalyst |
| HA HARPHarpoon Therapeutics Inc | $23.01+0.0% | — | 2 assetsStage unavailable | No dated catalyst |